Snow Brand Milk Products Co., Ltd.

Shunichi Dosako

Tadashi Idota

Yoshihiro Kawasaki

Eiki Deya

Morimasa Tanimoto

Hiroshi Shinmoto

Hiroko Kusano

Hiroko Isoda

Hiroshi Kawakami

Naoki Yamamoto

Toshio Sakurai

Kaoru Sato

Masaharu Shimatani

Hideki Nakashima

Kenkichi Ahiko

Tsuguaki Nishiya

Maki Shi Tanaka

Wataru Motsuchi

Shigeaki Tanaka

Naomichi Kobayashi

Seiichiro Tadokoro

Honoo Hashiba

Yoshikiko Honda

Hirokazu Furuya

Rika Shinooka

Toshihide Kabuki

Fumio Ito

Megumi Arai

Hadjime Nakajima

A mango kernel triturate or mango kernel extract has a bacteriostatic and antibacterial activity, and thus can be used in food products or cosmetics as a bacteriostatic and antibacterial agent. Furthermore, agents for preventing and treating acne or agents for preventing dental caries can be provided by adding said extract as an effective component.

Bacteriostatic and antibacterial agent containing mango kernel component

The invention relates to compositions and methods for inhibiting infection or suppressing growth of human immunodeficiency virus. The composition comprises, as an effective component, an iron-binding protein (e.g., lactoferrin, transferrin, ovotransferrin), a chemically modified compound of the iron-binding protein, or a hydrolyzed compound of the iron-binding protein. The effective components are safe and can be easily prepared from inexpensive raw materials. The composition can be orally administered, injected or applied to the skin, eye, ear, nose or used as a preparation for vagina affusion, mouth washing or suppositories, and can effectively inhibit infection or suppress growth of human immunodeficiency virus.

Composition for suppressing infection and growth of human

Iron lactoferrin complexes and preparation thereof

Disclosed herein is an infection protectant which is excellent in infection protective effects and is also safe. .kappa.-Casein, a sialic-acid-conjugated protein derived from cow milk, and a glycomacropeptide derived from .kappa.-casein, each of which is useful as an active ingredient in this invention, have been found to be effective for the prevention of adhesion of E. coli on cells and also for the inhibition of transformation of lymphocytes by EBV and also to have strong HI activity against virus. The infection protectant of this invention is hence believed to exhibit marked effects for the prevention of occurrence of infectious diarrhea, for mass protection against spreading of influenza, and also against canceration of lymphocytes. Since the active ingredient of the infection protectant is a substance derived from cow milk, it is free of any problem from the viewpoint of safety. Moreover, it is absolutely tasteless and odorless. It can therefore be added to foods for its application.

Infection protectant

Sialic acid binding proteins, sialic acid-binding peptides and sialic acid containing oligo-saccharides are active ingredients of a novel bacterial enterotoxin neutralizer and interfere with the binding of enterotoxins, including cholera toxin, to receptors so as to exert an effect of neutralizing the toxicity, thus being utilized as an effective neutralizer and are safe and available cheaply and abundantly from by-products produced during the processing of cow's milk which renders the enterotoxin neutralizer economically advantageous for commercial use.

Bacterial toxin neutralizer

The present invention provides a process for producing .kappa.-casein glycomacropeptides which comprises contacting milk raw materials containing .kappa.-casein glycomacropeptides having the pH value of 4 or lower with an anion exchanger; collecting by elution of a fraction which adsorbs on the anion exchanger; and concentrating and desalinating the eluted solution to obtain the .kappa.-casein glycomacropeptide.

Process for producing K-casein glycomacropeptides

The present invention provides a process for producing a .kappa.-casein glycomacropeptide comprising contacting milk raw materials containing the .kappa.-casein glycomacropeptide with an ion exchanger; collecting a fraction which does not adsorb on the ion exchanger; and concentrating and desalting the fraction to obtain the .kappa.-casein glycomacropeptide.

Process for producing .kappa.-casein glycomacropeptides

A rotary column is rotatably mounted on a hollow shaft having orifices and the shaft is journaled in a reaction vessel. The rotary column has an outer net around the shaft and a space defined by this outer net within the rotary column is divided by partition plates provided with many through-holes into several compartments to be loaded with carriers and immobilized enzymes. The reaction vessel is provided radially outside the compartments with a top cover so that carriers and immobilized enzymes may be easily and evenly loaded into the rotary column. An end surface of the rotary column that is remote from the drive mechanism is provided with a lateral cover. There are provided hydraulic cylinders to tilt the rotary column. Within the reaction vessel, the outer net of the rotary column is provided with rollers adjacent to the lateral cover. Furthermore, there is provided a deaerating pipe within the rotary column and the orifices of the hollow shaft are so dimensioned that, nearer a solution outlet, the diameters of the orifices are larger.

Rotary column reactor

An aqueous lactoferrin solution can be thermally treated for heat pasteurization or spray drying purposes substantially without impairing the iron-binding ability of the lactoferrin by first adjusting the ionic strength thereof in accordance with the formulae, wherein I is ionic strength and T is temperature (.degree.C.):

Method for thermally treating lactoferrin

Disclosed herein is a process for the efficient production of .kappa.-casein GMP on an industrial scale. The production of high-purity .kappa.-casein GMP is realized by using an effluent of rennet-casein curd free of whey proteins, lactose and the like as a starting effluent, adjusting the pH of the effluent to an acidic range to remove calcium phosphate and then subjecting the resulting effluent to a desalting treatment. .kappa.-Casein GMP is used as a standard substance for the assay of sialic acid. It has also attracted attention for its physiological activities and other properties.

Process for the production of .kappa.-casein glycomacropeptide

The present invention provides an agent utilizing for immunological assays in medical fields for blocking nonspecific adsorption, a process for preparing thereof and a method of blocking nonspecific adsorption. The agent contains a combination of milk protein as an effective constituent and a buffer solution containing one or more principal constituents selected from the group of organic acids and their salts.

Agent for blocking nonspecific adsorption, process for preparing thereof

This invention discloses a method for separating a highly pure form of bovine lactoferrin from cow's milk and purifying same which comprises preparing an affinity-chromatographic column by fixing a monoclonal antibody against bovine lactoferrin to an insoluble carrier; passing milk or a solution of bovine lactoferrin derived from cow'milk through the affinity-chromatographic column; and then eluting the bovine lactoferrin adsorbed to the affinity-chromatographic column.

Growing community of inventors

Urawa, Japan

Shunichi Dosako